American Stock Exchange Accepts ONI BioPharma Inc.'s Revised Plan of Compliance

ALACHUA, FL , a biopharmaceutical company, today announced it had received notice that the American Stock Exchange ("AMEX") has accepted the Company's Revised Plan of Compliance to regain compliance with the applicable listing standards by October 27, 2008.

As previously announced, on May 14, 2008, the Company received notice from the AMEX Staff indicating that the Company is below certain of the Exchange's continued listing standards due to the Company's shareholders' equity of less than $4,000,000 and losses from continuing operations and net losses in three of its four most recent fiscal years. Subsequently, the Company submitted a revised plan of compliance. On June 23, 2008, AMEX notified the Company that it accepted the Company's Revised Plan of Compliance and that the Company's extension to regain compliance with the continued listing standards would remain October 27, 2008, at which time the Company plans to be in full compliance with AMEX listing requirements.

The Company will be subject to periodic review by Exchange Staff during the extension period.

Stanley B. Stein, the Company's President and CEO, stated, "We are tremendously pleased with AMEX's acceptance of our Revised Plan of Compliance and look forward to a reinvigorated, healthy relationship with AMEX. We intend to accelerate the commercialization of our core technologies in conformity with our Revised Plan, so that we will achieve and surpass relevant Exchange standards in the future."

About ONI BioPharma Inc.

ONI BioPharma Inc. is a biopharmaceutical company with a pipeline of unique proprietary technologies, some of which are being commercialized. The Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The Company has developed platform technologies with respect to its products, thereby creating a pipeline of future products, which the Company expects to develop.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect ONI BioPharma's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact: ONI BioPharma Inc. Stanley B. Stein 386-418-4018 X222 www.oragenics.com